Trump Sets 100% Tariff on Generic Drugs With Two-Year Delay

President Donald Trump announced a 100% import tariff on generic drugs, effective August 2028, giving manufacturers a two-year window to relocate production to the United States. The move targets the supply chain for low-cost medicines, the majority of which are currently imported.

The tariff represents one of the most aggressive trade actions aimed at reshoring pharmaceutical manufacturing. Generic drugs account for approximately 90% of prescriptions filled in the U.S., with a significant portion of active pharmaceutical ingredients sourced from overseas facilities, particularly in China and India.

The two-year implementation delay provides a transition period for manufacturers to build or shift capacity domestically. However, the timeline raises questions about the feasibility of constructing compliant facilities and securing FDA approvals before the August 2028 deadline.

Major pharmaceutical distributors and manufacturers with significant generic exposure may face margin pressure or capital expenditure increases to comply. The policy could also impact healthcare costs if supply constraints emerge or if domestic production proves more expensive than current import structures.